Donaldson Capital Management LLC Has $1.03 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Donaldson Capital Management LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,698 shares of the biopharmaceutical company’s stock after selling 197 shares during the quarter. Donaldson Capital Management LLC’s holdings in Gilead Sciences were worth $1,029,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Altshuler Shaham Ltd grew its holdings in Gilead Sciences by 7.0% during the fourth quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 121 shares in the last quarter. Nilsine Partners LLC grew its stake in Gilead Sciences by 1.1% in the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after purchasing an additional 127 shares during the period. Etesian Wealth Advisors Inc. grew its stake in Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares during the period. Financial Counselors Inc. grew its stake in Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 128 shares during the period. Finally, Revolve Wealth Partners LLC grew its stake in Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 130 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

GILD traded down $0.34 during trading on Tuesday, reaching $67.41. 683,036 shares of the company were exchanged, compared to its average volume of 7,284,943. The company’s 50-day moving average is $72.61 and its two-hundred day moving average is $76.78. The company has a market cap of $83.93 billion, a price-to-earnings ratio of 15.06, a P/E/G ratio of 0.86 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12-month low of $67.19 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the company posted $1.67 EPS. Research analysts forecast that Gilead Sciences, Inc. will post 7.08 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.77 dividend. The ex-dividend date was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.57%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of recent analyst reports. Royal Bank of Canada reduced their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. Oppenheimer reduced their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, February 12th. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 26th. Finally, Cantor Fitzgerald dropped their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $85.36.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.